ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeNo recent work listed

Wan-Wen Weng

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102272366. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2022: 1 paper

Papers 1

Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. Co-author DOI 10.1016/j.heliyon.2022.e12064 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Donghai Jiang · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
Kwabena Gyabaah Owusu-Ansah · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
Jiawei Hong · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗
Shusen Zheng · 1 shared paper, 2022 · strength 0.19
- Paper Pralatrexate mediates effective killing of gemcitabine-resistant pancreatic cancer: role of mTOR/4E-BP1 signal pathway. DOI 10.1016/j.heliyon.2022.e12064 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.